Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal]
ImmunoTargets and Therapy · 2026-08 · Volume 15 · 1-1
DOI: 10.2147/itt.s645886 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoTargets and Therapy, 2026-08. Verfasst von Małgorzata Mitura-Lesiuk und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mitura-Lesiuk, M., Najda, P., Rdzanek, O., Bogucka, J., Różycka, K., Dubaj, M., & Zawitkowska, J. (2026). Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal]. ImmunoTargets and Therapy, Volume 15, 1-1. https://doi.org/10.2147/itt.s645886
Vancouver
Mitura-Lesiuk M, Najda P, Rdzanek O, Bogucka J, Różycka K, Dubaj M, et al. Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal]. ImmunoTargets and Therapy. 2026;Volume 15:1-1. doi:10.2147/itt.s645886
BibTeX
@article{MituraLesiuk2026,
author = {Mitura-Lesiuk, Małgorzata and Najda, Patrycja and Rdzanek, Oliwia and Bogucka, Julia and Różycka, Karolina and Dubaj, Maciej and Zawitkowska, Joanna},
title = {Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal]},
journal = {ImmunoTargets and Therapy},
year = {2026},
volume = {Volume 15},
pages = {1--1},
doi = {10.2147/itt.s645886}
}
EUVIMED